CCK₂ receptor antagonists

Bibliography

• NOBLE F, WANK SA, CRAWLEY JN et al.: International Union of Pharmacology. XXI. Structure, distribution and functions of cholecystokinin receptors. Biological actions of cholecystokinin. Pharmacol. Rev. (1999) 51:745–781.
   Google Scholar
• JENSEN RT, LEMP GF, GARDNER JD: Interactions of COOH-terminal fragments of cholecystokinin with receptors on dispersed acini from guinea-pig pancreas. J. Biol. Chem. (1982) 257:5554–5559.
   PubMed Web of Science ®Google Scholar
• INNIS RB SNYDER SH: Distinct cholecystokinin receptors in brain and pancreas. Proc. Nat. Acad. ScL (1980) 77:6917.
   PubMed Web of Science ®Google Scholar
• WANK SA: Cholecystokinin receptors. Am. J. Physiology(1995) 269:G628–G646.
   Google Scholar
• SANDVIK AK, WALDUM HL: CCK-B (gastrin) receptorregulates gastric histamine release and acid secretion. Am. J. Physiol (1991) 260:G925–G928.
   Google Scholar
• WALSH JH: Role of gastrin as a trophic hormone.Digestion (1990) 47:11–16.
   PubMed Web of Science ®Google Scholar
• JENSEN RT: CCKB/gastrin receptor antagonists: recentadvances and potential uses in gastric secretory disorders. Yale J. Biol. Med. (1996) 69:245–259.
   PubMed Web of Science ®Google Scholar
• CRESPI F: Ch o le cy sto kin in -B (CCK-B) receptor antago-nists improve "aged" sleep: a new class of sleep modulators? Methods Find. Exp. Clin. Pharmacol. (1999) 21:31–38
   Google Scholar
• MURPHY MG, SYTNIK B, KOVACS TOG et al.: The gastrin-receptor antagonist L-365,260 inhibits stimulated acid secretion in humans. Clin. Pharmacol Ther. (1993) 5 4 (4):533–539
   Google Scholar
• ••First description of the effect on gastric acid secretion of aCCK2 receptor antagonist in humans.
   Google Scholar
• BELTINGER J, HILDEBRAND P, HOWALD A, DAMATO M,BEGLINGER C: Effect of CR2194, a novel CCKB/gastrin-recep tor antagonist, on gastrin-stimulated acid secretion in man. Gastroenterology (1994) 1 06 (4) (suppl.): Abstract A50.
   Google Scholar
• BRAD WEJN J, KOSZYCKI D, COUETOUX DU TETRE A etal.: The panicogenic effects of cholecystokinin-tetrapeptide are antagonised by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch. Gen. Psychiatry (1994) 51:486–493.
   Google Scholar
• WESTENBERG HGM, VAN MEGEN HJGM, DEN BOER JA:Effects of the cholecystokinin-B antagonist L-365,260 on lactate-induced panic disorder (PD) patients. Psychopharmacol. Bull. (1994) 30 (4):644.
   Google Scholar
• KRAMER MS, CUTLER N, BALLENGER JC et al: A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder. Biol. Psychiatry (1995) 37:462–466.
   PubMed Web of Science ®Google Scholar
• BRADWEJN J, KOSZYCKI D, PARADIS M et al.: Effect ofCI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers. Biol. Psychiatry (1995) 38:742–746.
   PubMed Web of Science ®Google Scholar
• ADAMS JB, PYKE RE, COSTA J et al.: A double-blind,placebo-controlled study of a CCK-B receptor antago-nist, CI-988, in patients with generalised anxiety disorder. J. Clin. Psychopharmacol. (1995) 15(6):428–434.
   PubMed Web of Science ®Google Scholar
• VAN MEGEN HJGM, WESTENBERG HGM, DEN BOER JA etal.: The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients. Psychopharmacology (1 99 7) 129:243–248.
   Google Scholar
• LOWE III JA: Cholecystokinin-B receptor antagonists.Exp. Opin. Ther. Patents (1995) 5(3):231–237
   Google Scholar
• CHANG RSL, LOTTI V, MONAGHAN J et al.: A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus. Science (1985) 230:177–179.
   PubMed Web of Science ®Google Scholar
• •The pharmacological characterisation of the natural product asperlicin.
   Google Scholar
• EVANS BE, BOCK M: Promiscuity in receptor ligand research. In: Advances in Medicinal Chemistry. Maryanoff BE, Maryanoff CA (Eds), JAI press, Inc., Greenwich, CT, USA. (1993):111–152.
   Google Scholar
• •Detailed insight into the development from Asperlicin of 1,4-benzodiazepines as CCK receptor antagonists.
   Google Scholar
• BOCK MG, DIPARDO RM, EVANS BE et al: Development of 1,4-benzodiazepine cholecystokinin type B antago-nists. J. Med. Chem. (1993) 36:4276–4292.
   PubMed Web of Science ®Google Scholar
• CHAMBERS MS, HOBBS SC, GRAHAM MI et al: Potent, selective and water-soluble benzodiazepine-based CCKB receptor antagonists that contain lipophilic carboxylate surrogates. Bioorg. Med. Chem. Letts. (1995) 5:2303–2308.
   Web of Science ®Google Scholar
• PATEL S, CHAPMAN KL, HEALD A, SMITH AJ, FREEDMANSB: Measurement of central nervous system activity of systemically administered CCKB receptor antagonists by ex vivo binding. Eur. J. Pharm. (1994) 253:237–244.
   PubMed Web of Science ®Google Scholar
• BOCK MG, DIPARDO RM, MELLIN EC et al: Second-generation benzodiazepine CCK-B antagonists. Development of subnanomolar analogs with selectivity and water solubility. J Med. Chem. (1994) 37:722–724.
   Google Scholar
• CASTRO JL, BALL RG, BROUGHTON HB et al.: Controlledmodification of acidity in cholecystokinin-B receptor antagonists: N-(1, 4 -benzodiazepin-3 -y1)41/43-(tetrazol-5-ylamino)phenyllureas. J Med. Chem. (1996) 39:842–849.
   PubMed Web of Science ®Google Scholar
• SHOWELL GA, BOURRAIN S, NEDUVELIL JG et al.:High-affinity and potent, water-soluble 5-amino-1,4-benzodiazepine CCKB/gastrin receptor antagonists containing a cationic solubilising group . Med. Chem. (1994) 37:719–721.
   Web of Science ®Google Scholar
• CASTRO JL, BROUGHTON HB, RUSSELL MGN et al: 5 -(Piperidin-2 -y1)- and 5 -(homopiperidin-2-y1)-1,4-benzodiazepines: high-affinity, basic ligands for the cholecystokinin-B receptor. J. Med. Chem. (1997) 40:2491–2501.
   PubMed Web of Science ®Google Scholar
• SHOWELL GA, BOURRAIN S, FLETCHER SR et al.: C5-piperaziny1-1,4-benzodiazepines, water-soluble, orally bioavailableCCKB/gastrin receptor antagonists. Bioorg. Med. Chem. Letts. (1995) 5:3023–3026.
   Google Scholar
• PATEL S, SMITH AJ, CHAPMAN KL et al: Biological properties of the benzodiazepine amidine derivative L-740,093, a cholecystokinin-B/gastrin receptor antagonist with high affinity in vitro and high potency in vivo. Mol. Pharm. (1994) 46:943–948.
   PubMed Web of Science ®Google Scholar
• SELNICK HG, LIVERTON NJ, BALDWIN JJ et al: Class IIIantiarrythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IK by (R)-2-(2,4-trifluoromethyl)-N42 -ox o-5 -ph enyl-1 -(2,2,2 -trifluor o ethyl)-2,3- dihydro- 1 H-benzo [e][1,4]diazepin-3-yl]acetamide. Med. Chem. (1997) 40:3865–3868.
   Web of Science ®Google Scholar
• SATOH M, KONDOH Y, OKAMOTO Y et al.: New 1, 4-benzodiazepin-2-one derivatives as gastrin/ cholecystokinin -B antagonists. Chem. Pharm. (1995) 43:2159–2167.
   Google Scholar
• NISHIDA A, MIYATA K, TSUTSUMI R et al.: Pharma-cological profile of (R)-142,3-dihydro-1-(2'-methyl phenacy1)-2 -ox o-5-pheny1-1 H-1, 4-benzodiazepin-3-y11-3-(3-methylphenyOurea (YM022), a new potent and selective gastrin /cholecystokinin-B receptor antagonist, in vitro and in vivo. J. Pharmacol Exp. Therap. (1994) 269:725–731.
   PubMed Web of Science ®Google Scholar
• YANO K, KAJIYAMA A, YAMAZAKI S et al.: In vitro stability and in vivo absorption studies of colloidal particles formed from a solid dispersion system. Chem. Pharm. Bull. (1996) 44:2309–2313.
   PubMed Web of Science ®Google Scholar
• NISHIDA A, TAKINAMI Y, YUKI H et al.: YM022 {(R)-142,3-dihydro-1 -(2t-methylphenacy1)-2-ox o-5-phenyl-1 H-1, 4-b enzodiazepin -3 -y1]-3-(3 -methyl-ph enyl)ureal, a potent and selective gastrin/ cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats. J. Pharmacol. Exp. Therap. (1994) 270:1256–1261.
   PubMed Web of Science ®Google Scholar
• SEMPLE G, RYDER H, KENDRICK DA et al.: Synthesis and biological activity of 5-heteroaryl benzodiazepines: analogues of YM022. Bioorg. Med. Chem. Letts. (1996) 6:55–58.
   Web of Science ®Google Scholar
• SATOH M, OKAMOTO Y, KOSHIO H et al.: Biological activity of analogues of YM022. Novel (3-amino substi-tuted phenyl)urea derivatives of 1,4-benzodiazepin-2-one as gastrin/cholecystokinin-B receptor antago-nists. Chem. Pharm. Bull. (1996) 44:1412–1414.
   Google Scholar
• TAKINAMI Y, YUKI H, NISHIDA A et al.: YE476 is a new potent and selective gastrin /cholecystokinin-B receptor antagonist in vitro and in vivo. Aliment. Pharmacol. Ther. (1997) 11:113–120.
   PubMed Web of Science ®Google Scholar
• SEMPLE G, RYDER H, ROOKER DP et al.: (3M-N-(1-tert-butylcar b onylmethyl)-2,3 -dihydro -2-ox o -5-(2-pyridy1)-1H-1,4-benzodiazepin-3-y1)-Ar-(3- (methyl-amino)phenyl)urea (YE476): a potent and orally active gastrin /CCK-B antagonist. J. Med. Chem. (1997) 40:331–341.
   PubMed Web of Science ®Google Scholar
• NISHIDA A, KOBAYASHI-UCHIDA A, AKUZAWA S et al.: Gastrin receptor antagonist YM022 prevents hypersecretion after long-term acid suppression. Am. Physiol (1997) 269:G699–G705.
   Web of Science ®Google Scholar
• BOYCE M, WARRINGTON S, JOHNSTON A, HARRIS A: Effect on gastric acid pH of single doses of YE476, a new gastrin antagonist, compared with Ranitidine and placebo. Proc. Br. Pharmacol Soc. (2000) C118.
   Google Scholar
• KATSUMI I, SATOH Y, MITSUI H et al.: Cholecystokinin (CCK)-B receptor antagonist: synthesis of NF-127. 16th Medicinal Chemistry Symposium. Toyama, Japan (1996) Abstract 155.
   Google Scholar
• SATOH Y, TABUCHI S, MITSUI H: Design of dual CCK-Aand CCK-B receptor antagonists. Drugs Future (1997) . 22:1117-1131.© Ashley Publications Ltd. All rights reserved.Exp. Opin. Ther. Patents (2001) 11(3)
   Google Scholar
• GAVIRAGHI G, CASSARA P, CORSI M et al.: Synthesis and structure-activity relationship of new 1,5 -benzo-diazepine CCK-B antagonists. Perspect. RecepL Res. (1996) 375–387.
   Google Scholar
• URSINI A, CAPELLI AM. CARR RAE et al: Synthesis and SAR of new 5-phenyl-3-ureido-1,5-benzodiazepines as cholecystokinin-B receptor antagonists. J. Med. Chem. (2000) 43:3596–3613.
   PubMed Web of Science ®Google Scholar
• BAILEY N, BOX PC, CARR RAE et al.: Novel1,5 -benzodiazepindione gastrin/CCKB antagonists. Bioorg. Med. Chem. Letts. (1997) 7:281–286.
   Web of Science ®Google Scholar
• HAGISHITA S, SENO K, KAMATA S et al: Potent andsubtype-selective CCK-B/gastrin receptor antagonists: 2,4-dioxo-1,5-benzodiazepines with a plane of symmetry. Bioorg. Med. Chem, (1997) 5 : 14 33–1 4 4 6 .
   Google Scholar
• BOCK MG, DIPARDO RM, VEBER DF et al: Benzolactamsas non-peptide cholecystokinin receptor ligands. Bioorg. Med. Chem. Letts. (1993) 3:871–874.
   Web of Science ®Google Scholar
• VAN NEIL MB, FREEDMAN SB, MATASSA VG et al.: CCKBselective receptor ligands: novel 1,3,5-trisubstituted benzazepin-2-ones. Bioorg. Med. Chem. Letts. (1995) 5:1421–1426.
   Web of Science ®Google Scholar
• LOWE III JA, HAGEMAN DL, DROZDA SE et al.: 5-phenyl-3-ureidobenzazepin-2-ones as cholecystokinin-B receptor antagonists. J. Med. Chem. (1994) 37:3789–3811.
   PubMed Web of Science ®Google Scholar
• LOWE III JA, DROZDA SE, MCLEAN S et al: A watersoluble benzazepine cholecystokinin-B receptor antagonist. Bioorg. Med. Chem. Letts. (1995) 5:1933–1936.
   Web of Science ®Google Scholar
• LOMBARDO F, WINTER SM, TREMAINE L, LOWE III JA:The anxieties of drug discovery and development: CCK-B receptor antagonists. Pharm. Biotechnol. (1998) 11:465–479
   PubMedGoogle Scholar
• YU MJ, THRASHER KJ, MCCOWAN JR, MASON NR, MENDELSOHN LG: Quinazolininone cholecystokinin-B receptor antagonists. J. Med. Chem. (1991) 3 4 : 1 5 08–1 5 1 1 .
   Google Scholar
• PADIA JK, CHILVERS H, DAUM P et al: Design and synthesis of novel nonpeptide CCK-B receptor antago-nists. Bioorg. Med. Chem. Letts. (1997) 7 : 80 5–8 1 0 .
   Google Scholar
• PADIA JK, FIELD M, HINTON J et al: Novel nonpeptide CCK-B antagonists: design and development of quinazolinone derivatives as potent, selective and orally active CCK-B antagonists. J. Med. Chem. (1998) 41:1042–1049.
   PubMed Web of Science ®Google Scholar
• BERTRAND P, BOHME GA, DURIEUX C et al: Pharma-cological properties of ureido-acetamides, new potent and selective non-peptide CCKB/gastrin receptor antagonists. Eur. j Pharmacol (1994) 262:233–245.
   PubMed Web of Science ®Google Scholar
• PENDLEY CE, FITZPATRICK LR, CAPOLINO AJ et al: RP 73870, a novel gastrin/cholecystokinin-B receptor antagonist with potent anti-ulcer activity in the rat. J. Pharm. Exp. Ther. (1995) 273:1015–1022.
   PubMed Web of Science ®Google Scholar
• BERTRAND P, BOHME A, PIOT 0 et al.: RPR 101367, a new potent and selective non-peptide CCKB receptor antagonist. Br. J. Pharmacol (1995) 116 (suppl.): Abstract 241P.
   Google Scholar
• HAGISHITA S, MURAKAMI Y, SENO K et al.: Synthesis andpharmacological properties of ureidomethylcarba-moylphenylketone derivatives. A new potent and subtype-selective nonpeptide CCK-B/gastrin receptor antagonist, S-0509. Bioorg. Med. Chem. Letts. (1997) 5:1695–1714.
   Google Scholar
• TAKEDA Y, KAWAGOE K, YOKOMIZO A et al.: Synthesisof phenoxyacetic acid derivatives as highly potent antagonists of gastrin /cholecystokinin-B receptors. III Chem. Pharm. Bull. (1999) 47:755–771.
   PubMed Web of Science ®Google Scholar
• OGIHARA Y, HONDA Y, SHIMOTO Y: Pharmacologicalprofiles of D51-9927, a novel gastrin receptor antago-nist. Jpn. j Pharmacol (1997) 73 (suppl. 1): Abstract 0–38.
   Google Scholar
• ESAKI T, EMURA T, TACHIBANA K et al: Chiral indoloneacetamides: a new class of orally active CCK-B/gastrin antagonists. 14th International Symposium on Medicinal Chemistry. Maastricht, The Netherlands. (1996) Abstract P-3.04.
   Google Scholar
• BABA A, HOSHINO E, ONOMA M, ESAKI T, TAKEDA K:Pharmacological profiles of AG-041R, a novel selective gastrin/CCKB antagonist. Jpn. J. Pharmacol. (1995) 67 (supp1.1): Abstract P2–119.
   Google Scholar
• BABA A, HOSHINO E, ONOMA M, ESAKI T, TAKEDA K:Pharmacological profiles of AG-041R, a novel selective gastrin /CCKB antagonist. Gastroenterology (1995) 1 0 8 (4) (suppl.): Abstract A950.
   Google Scholar
• DING X-Q, LINDSTROM E, HAKANSON R: Evaluation ofthree novel cholecystokinin-B/gastrin receptor antagonists: a study of their effects on rat enter ochr omaffin -like cell activity. Pharmacol. Toxkol (1997) 81:232–237.
   PubMedGoogle Scholar
• HORWELL DC: Use of the chemical structure ofpeptides as the starting point to design nonpeptide agonists and antagonists at peptide receptors: examples with cholecystokinin and tachykinins. Bioorg. Med. Chem. (1996) 4:1573–1576.
   PubMed Web of Science ®Google Scholar
• MARVIK R, SANDVIK A, WALDUM HL: Evaluation of biologic gastrin activity of compound CI-988 in the isolated, vascularly perfused rat stomach. Scand. Gastroenterol. (1997) 32:519–522
   PubMed Web of Science ®Google Scholar
• TRIVEDI BK, PADIA JK, HOLMES A et al.: Second genera-tion `peptoid' CCK-B receptor antagonists: identifica-tion and development of N-(adamantyloxy-carbony1)-a-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile. J. Med. Chem. (1998) 41:38–45.
   PubMed Web of Science ®Google Scholar
• MAKOVEC F, PERIS W, REVEL L et al.: Structure-antigastrin activity relationships of new (1?)-4-benzamido-5-oxopentanoic acid derivatives. J Med. Chem. (1992) 35:28–38.
   PubMed Web of Science ®Google Scholar
• ROVATI LC, D'AMATO M, PERIS W, REVEL L, MAKOVEC F:Selectivity and potency of new basic CCK-B antago-nists. Ann. NY Acad. Sci. (1994) 713:395–397.
   PubMedGoogle Scholar
• MAKOVEC F, PERIS W, FRIGERIO S et al.: Structure-antigastrin activity relationships of new spiroglumide amido acid derivatives. J. Med. Chem. (1996) 39:135-142.© Ashley Publications Ltd. All rights reserved.Exp. Opin. Ther. Patents (2001) 11(3)
   Google Scholar
• REVEL L, MENNUNI L, LETARI 0, D'AMATO M, MAKOVEC F: Gastric acid antisecretive activity of CR2945, a new potent gastrin /CCKBreceptor antagonist. Gut (1997) 41 (suppl. 3): Abstract P005.
   Google Scholar
• KALINDJIAN SB, BUCK IM, DAVIES JMR et al.: Non-peptide cholecystokinin-B/gastrin receptor antagonists based on bicyclic, heteroaromatic skeletons. J. Med. Chem. (1996) 39:1806–1815
   PubMed Web of Science ®Google Scholar
• MCDONALD IM, DUNSTONE DJ, KALINDJIAN SB et al: 2,7-dioxo-2,3,4,5,6,7-hexahydro-1h-benzo[h][1,4]diaz onine as a new template for the design of CCK2 receptor antagonists. J. Med. Chem. (2000) 43:3518–3529
   PubMed Web of Science ®Google Scholar